Intellia Therapeutics Inc (NASDAQ:NTLA) Shares Shorted Rose By 13.15%

Intellia Therapeutics Inc (NASDAQ:NTLA) had an increase of its shares shorted by 13.15%. FINRA issued shares shorted of NTLA’s total 6.13M shares. The up change of 13.15% from 5.41 million shares was reported. 6 days will cost NTLA with 1.02 million average volume to recover its former position. Intellia Therapeutics Inc’s shares shorted float is 19.85%.

Ticker’s shares touched $14.82 during the last trading session after 1.33% change.Intellia Therapeutics, Inc. has volume of 179,136 shares. Since January 17, 2018 NTLA has declined 21.90% and is downtrending. NTLA underperformed by 21.90% the S&P 500.

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.The firm is worth $643.47 million. The firm develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.Currently it has negative earnings. The Company’s ex vivo pipeline includes proprietary and partnered programs focuses on chimeric antigen receptor T cells and hematopoietic stem cells.

For more Intellia Therapeutics, Inc. (NASDAQ:NTLA) news released briefly go to:,,, or The titles are as follows: “Is a Surprise Coming for Intellia Therapeutics (NTLA)This Earnings Season? – Nasdaq” released on March 09, 2018, “CFO of gene editing biotech Editas leaving for Bain – Boston Business Journal” on December 21, 2018, “VC firm Atlas ditches JP Morgan conference. Will others follow? – Boston Business Journal” with a publish date: January 14, 2019, “Why CRSP Stock Has Added Layers of Risk –” and the last “Intellia Therapeutics to Host Educational Briefing Webinar on Interference Proceedings Relating to CRISPR/Cas9 Genome Editing Technology Patents – GlobeNewswire” with publication date: August 23, 2018.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.